Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alembic Pharmaceuticals Ltd.

NSE: APLLTD | BSE: 533573 | ISIN: INE901L01018 | Industry: Pharmaceuticals
| Mid-range Performer

1025.4000 -5.10 (-0.49%)

NSE Jul 16, 2025 15:31 PM

41.40% Gain from 52W Low

Volume: 86,741

Alembic Pharmaceuticals Ltd.

11 Feb 2022

1025.40

-0.49%

Alembic Pharma (BUY): US business weak but showing signs of stabilising

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 revenue dipped 3% YoY on a steep decline in US (-23%) and API (-8%) business, despite growth in India (+17%) and ROW (+13%)

Alembic Pharmaceuticals Ltd. is trading above all available SMAs